1 6537 110 TRANSCRIPTIONAL REGULATOR PRDM12 IS ESSENTIAL FOR HUMAN PAIN PERCEPTION. PAIN PERCEPTION HAS EVOLVED AS A WARNING MECHANISM TO ALERT ORGANISMS TO TISSUE DAMAGE AND DANGEROUS ENVIRONMENTS. IN HUMANS, HOWEVER, UNDESIRABLE, EXCESSIVE OR CHRONIC PAIN IS A COMMON AND MAJOR SOCIETAL BURDEN FOR WHICH AVAILABLE MEDICAL TREATMENTS ARE CURRENTLY SUBOPTIMAL. NEW THERAPEUTIC OPTIONS HAVE RECENTLY BEEN DERIVED FROM STUDIES OF INDIVIDUALS WITH CONGENITAL INSENSITIVITY TO PAIN (CIP). HERE WE IDENTIFIED 10 DIFFERENT HOMOZYGOUS MUTATIONS IN PRDM12 (ENCODING PRDI-BF1 AND RIZ HOMOLOGY DOMAIN-CONTAINING PROTEIN 12) IN SUBJECTS WITH CIP FROM 11 FAMILIES. PRDM PROTEINS ARE A FAMILY OF EPIGENETIC REGULATORS THAT CONTROL NEURAL SPECIFICATION AND NEUROGENESIS. WE DETERMINED THAT PRDM12 IS EXPRESSED IN NOCICEPTORS AND THEIR PROGENITORS AND PARTICIPATES IN THE DEVELOPMENT OF SENSORY NEURONS IN XENOPUS EMBRYOS. MOREOVER, CIP-ASSOCIATED MUTANTS ABROGATE THE HISTONE-MODIFYING POTENTIAL ASSOCIATED WITH WILD-TYPE PRDM12. PRDM12 EMERGES AS A KEY FACTOR IN THE ORCHESTRATION OF SENSORY NEUROGENESIS AND MAY HOLD PROMISE AS A TARGET FOR NEW PAIN THERAPEUTICS. 2015 2 4514 21 MULTI-OMICS ANALYSIS REVEALS CHANGES IN THE INTESTINAL MICROBIOME, TRANSCRIPTOME, AND METHYLOME IN A RAT MODEL OF CHRONIC NON-BACTERIAL PROSTATITIS: INDICATIONS FOR THE EXISTENCE OF THE GUT-PROSTATE AXIS. CHRONIC NON-BACTERIAL PROSTATITIS (CNP) IS ONE OF THE MOST PREVALENT DISEASES IN HUMAN MALES WORLDWIDE. IN 2005, THE PROSTATE-GUT AXIS WAS FIRST PROPOSED TO INDICATE THE CLOSE RELATIONSHIP BETWEEN THE PROSTATE AND THE INTESTINE. THIS STUDY INVESTIGATED CNP-INDUCED CHANGES OF THE GUT MICROBIOTA, GENE EXPRESSION AND DNA METHYLATION IN A RAT MODEL BY USING MULTI-OMICS ANALYSIS. FIRSTLY, 16S RDNA SEQUENCING PRESENTED AN ALTERED STRUCTURE OF THE MICROBIOTA IN CECUM OF CNP RATS. THEN, TRANSCRIPTOMIC ANALYSIS REVEALED THAT THE EXPRESSION OF 185 GENES IN INTESTINAL EPITHELIUM WAS SIGNIFICANTLY CHANGED BY CNP. THESE CHANGES CAN PARTICIPATE IN THE IMMUNE SYSTEM, DIGESTIVE SYSTEM, METABOLIC PROCESS, ETC. FINALLY, METHYLC-CAPTURE SEQUENCING (MCC-SEQ) FOUND 73,232 DIFFERENTIALLY METHYLATED SITES (DMSS) IN THE DNA OF INTESTINAL EPITHELIUM BETWEEN CONTROL AND CNP RATS. A COMBINED ANALYSIS OF METHYLOMICS AND TRANSCRIPTOMICS SUGGESTED AN EPIGENETIC MECHANISM FOR CNP-INDUCED DIFFERENTIAL EXPRESSION GENES CORRELATED WITH INTESTINAL BARRIER FUNCTION, IMMUNITY, METABOLISM, ENTERIC INFECTIOUS DISEASE, ETC. MORE IMPORTANTLY, THE TRANSCRIPTOMIC, METHYLOMIC AND GUT MICROBIAL CHANGES WERE HIGHLY CORRELATED WITH MULTIPLE PROCESSES INCLUDING INTESTINAL IMMUNITY, METABOLISM AND EPITHELIAL BARRIER FUNCTION. IN THIS STUDY, DISRUPTED HOMEOSTASIS IN THE GUT MICROBIOTA, GENE EXPRESSION AND DNA METHYLATION WERE REPORTED IN CNP, WHICH SUPPORTS THE EXISTENCE OF THE GUT-PROSTATE AXIS. 2021 3 4229 20 METHYLATION OF INK4 AND CIP/KIP FAMILIES OF CYCLIN-DEPENDENT KINASE INHIBITOR IN CHRONIC LYMPHOCYTIC LEUKAEMIA IN CHINESE PATIENTS. BACKGROUND: INK4 (P15, P16, P18 AND P19) AND CIP/KIP (P21, P27 AND P57) ARE TWO FAMILIES OF CYCLIN-DEPENDENT KINASE INHIBITORS (CKI) TARGETING CDK4/6 AND CDK2, RESPECTIVELY. AIM: TO STUDY THE ROLE OF METHYLATION IN THE INACTIVATION OF CKI IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL). MATERIALS AND METHODS: METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION WAS CARRIED OUT ON DNA OBTAINED FROM THE BONE MARROW OF 56 NEWLY DIAGNOSED PATIENTS WITH CLL. RESULTS: SIMILAR DEMOGRAPHIC FEATURES AND CLINICAL OUTCOME WERE OBSERVED IN OUR PATIENTS WHEN COMPARED WITH CAUCASIAN PATIENTS, INCLUDING AN INDOLENT CLINICAL COURSE (10-YEAR OVERALL SURVIVAL 51%) AND ADVANCED RAI STAGE (P = 0.006), AND A HIGH-RISK KARYOTYPE SUCH AS TRISOMY 12 AND COMPLEX ABERRATIONS (P = 0.03). IN THE INK4 FAMILY, METHYLATION IN P15 AND P16 OCCURRED IN 20 (35.7%) AND 8 (14.3%) PATIENTS, RESPECTIVELY. IN ALL, 5 (8.9%) CLL SAMPLES HARBOURED CONCURRENT METHYLATION OF BOTH P15 AND P16. APART FROM AN ASSOCIATION OF P16 METHYLATION WITH HIGHER PRESENTING LEUCOCYTE COUNT (64.5 X 10(9)/L IN METHYLATED P16 AND 16.0 X 10(9)/L IN UNMETHYLATED P16 PATIENTS; P = 0.016), THERE WAS NO ASSOCIATION BETWEEN P15 AND P16 METHYLATION AND AGE, SEX AND RAI STAGE. NO DIFFERENCE WAS OBSERVED IN THE OVERALL SURVIVAL FOR PATIENTS WITH AND WITHOUT P15 AND P16 METHYLATION. BY CONTRAST, P18 AND RB WERE UNMETHYLATED IN ALL SAMPLES. IN THE CIP/KIP FAMILY, APART FROM INFREQUENT METHYLATION OF P57 IN 4 (7.1%) PATIENTS, METHYLATION OF P21 AND P27 WAS UNIFORMLY ABSENT. CONCLUSION: P15 AND, LESS FREQUENTLY, P16 OF THE INK4 FAMILY OF CKI, INSTEAD OF THE CIP OR KIP FAMILY, WERE TARGETED BY METHYLATION IN CLL. P16 METHYLATION WAS ASSOCIATED WITH A HIGHER LYMPHOCYTE COUNT AT PRESENTATION. THIS IS THE FIRST COMPREHENSIVE STUDY OF THE EPIGENETIC DYSREGULATION OF THE INK4 AND CIP/KIP FAMILIES OF CKI IN CHINESE PATIENTS WITH CLL. 2006 4 5155 31 PRDM12 MODULATES PAIN-RELATED BEHAVIOR BY REMODELING GENE EXPRESSION IN MATURE NOCICEPTORS. PRDM12 IS A CONSERVED EPIGENETIC TRANSCRIPTIONAL REGULATOR THAT DISPLAYS RESTRICTED EXPRESSION IN NOCICEPTORS OF THE DEVELOPING PERIPHERAL NERVOUS SYSTEM. IN MICE, PRDM12 IS REQUIRED FOR THE DEVELOPMENT OF THE ENTIRE NOCICEPTIVE LINEAGE. IN HUMANS, PRDM12 MUTATIONS CAUSE CONGENITAL INSENSITIVITY TO PAIN, LIKELY BECAUSE OF THE LOSS OF NOCICEPTORS. PRDM12 EXPRESSION IS MAINTAINED IN MATURE NOCICEPTORS SUGGESTING A YET-TO-BE EXPLORED FUNCTIONAL ROLE IN ADULTS. USING PRDM12 INDUCIBLE CONDITIONAL KNOCKOUT MOUSE MODELS, WE REPORT THAT IN ADULT NOCICEPTORS PRDM12 IS NO LONGER REQUIRED FOR CELL SURVIVAL BUT CONTINUES TO PLAY A ROLE IN THE TRANSCRIPTIONAL CONTROL OF A NETWORK OF GENES, MANY OF THEM ENCODING ION CHANNELS AND RECEPTORS. WE FOUND THAT DISRUPTION OF PRDM12 ALTERS THE EXCITABILITY OF DORSAL ROOT GANGLION NEURONS IN CULTURE. PHENOTYPICALLY, WE OBSERVED THAT MICE LACKING PRDM12 EXHIBIT NORMAL RESPONSES TO THERMAL AND MECHANICAL NOCICEPTIVE STIMULI BUT A REDUCED RESPONSE TO CAPSAICIN AND HYPERSENSITIVITY TO FORMALIN-INDUCED INFLAMMATORY PAIN. TOGETHER, OUR DATA INDICATE THAT PRDM12 REGULATES PAIN-RELATED BEHAVIOR IN A COMPLEX WAY BY MODULATING GENE EXPRESSION IN ADULT NOCICEPTORS AND CONTROLLING THEIR EXCITABILITY. THE RESULTS ENCOURAGE FURTHER STUDIES TO ASSESS THE POTENTIAL OF PRDM12 AS A TARGET FOR ANALGESIC DEVELOPMENT. 2022 5 2450 29 EPIGENETIC SUPPRESSION OF LIVER X RECEPTOR BETA IN ANTERIOR CINGULATE CORTEX BY HDAC5 DRIVES CFA-INDUCED CHRONIC INFLAMMATORY PAIN. BACKGROUND: LIVER X RECEPTORS (LXRS), INCLUDING LXRALPHA AND LXRBETA, ARE KEY REGULATORS OF TRANSCRIPTIONAL PROGRAMS FOR BOTH CHOLESTEROL HOMEOSTASIS AND INFLAMMATION IN THE BRAIN. HERE, THE MODES OF ACTION OF LXRS AND THE EPIGENETIC MECHANISMS REGULATING LXRBETA EXPRESSION IN ANTERIOR CINGULATE CORTEX (ACC) OF CHRONIC INFLAMMATORY PAIN (CIP) ARE INVESTIGATED. METHODS: THE DEFICIT OF LXR ISOFORM AND ANALGESIC EFFECT OF LXR ACTIVATION BY GW3965 WERE EVALUATED USING THE MOUSE MODEL OF CIP INDUCED BY HINDPAW INJECTION OF COMPLETE FREUND'S ADJUVANT (CFA). THE MECHANISMS INVOLVED IN GW-MEDIATED ANALGESIC EFFECTS WERE ANALYZED WITH IMMUNOHISTOCHEMICAL METHODS, ELISA, CO-IMMUNOPRECIPITATION (CO-IP), WESTERN BLOT, AND ELECTROPHYSIOLOGICAL RECORDING. THE EPIGENETIC REGULATION OF LXRBETA EXPRESSION WAS INVESTIGATED BY CHROMATIN IMMUNOPRECIPITATION, QUANTITATIVE REAL-TIME PCR, AND SEQUENCING. RESULTS: WE REVEALED THAT CFA INSULT LED TO LXRBETA REDUCTION IN ACC, WHICH WAS ASSOCIATED WITH UPREGULATED EXPRESSION OF HISTONE DEACETYLASE 5 (HDAC5), AND KNOCKDOWN OF LXRBETA BY SHRNA LED TO THERMAL HYPERALGESIA. CO-IP SHOWED THAT LXRBETA INTERACTED WITH NF-KAPPAB P65 PHYSICALLY. LXRBETA ACTIVATION BY GW3965 EXERTED ANALGESIC EFFECTS BY INHIBITING THE NUCLEAR TRANSLOCATION OF NF-KAPPAB, REDUCING THE PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN KINASES (MAPKS) IN ACC, AND DECREASING THE PROMOTED INPUT-OUTPUT AND ENHANCED MEPSC FREQUENCY IN ACC NEURONS AFTER CFA EXPOSURE. IN VITRO EXPERIMENTS CONFIRMED THAT HDAC5 TRIGGERED HISTONE DEACETYLATION ON THE PROMOTER REGION OF LXRBETA, RESULTING IN DOWNREGULATION OF LXRBETA TRANSCRIPTION. CONCLUSION: THESE FINDINGS HIGHLIGHT AN EPIGENETIC MECHANISM UNDERLYING LXRBETA DEFICITS LINKED TO CIP, AND LXRBETA ACTIVATION MAY REPRESENT A POTENTIAL NOVEL TARGET FOR THE TREATMENT OF CIP WITH AN ALTERATION IN INFLAMMATION RESPONSES AND SYNAPTIC TRANSMISSION IN ACC. 2019 6 2993 34 GENETIC PAIN LOSS DISORDERS. GENETIC PAIN LOSS INCLUDES CONGENITAL INSENSITIVITY TO PAIN (CIP), HEREDITARY SENSORY NEUROPATHIES AND, IF AUTONOMIC NERVES ARE INVOLVED, HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY (HSAN). THIS HETEROGENEOUS GROUP OF DISORDERS HIGHLIGHTS THE ESSENTIAL ROLE OF NOCICEPTION IN PROTECTING AGAINST TISSUE DAMAGE. PATIENTS WITH GENETIC PAIN LOSS HAVE RECURRENT INJURIES, BURNS AND POORLY HEALING WOUNDS AS DISEASE HALLMARKS. CIP AND HSAN ARE CAUSED BY PATHOGENIC GENETIC VARIANTS IN >20 GENES THAT LEAD TO DEVELOPMENTAL DEFECTS, NEURODEGENERATION OR ALTERED NEURONAL EXCITABILITY OF PERIPHERAL DAMAGE-SENSING NEURONS. THESE GENETIC VARIANTS LEAD TO HYPERACTIVITY OF SODIUM CHANNELS, DISTURBED HAEM METABOLISM, ALTERED CLATHRIN-MEDIATED TRANSPORT AND IMPAIRED GENE REGULATORY MECHANISMS AFFECTING EPIGENETIC MARKS, LONG NON-CODING RNAS AND REPETITIVE ELEMENTS. THERAPIES FOR PAIN LOSS DISORDERS ARE MAINLY SYMPTOMATIC BUT THE FIRST TARGETED THERAPIES ARE BEING TESTED. CONVERSELY, CHRONIC PAIN REMAINS ONE OF THE GREATEST UNRESOLVED MEDICAL CHALLENGES, AND THE GENES AND MECHANISMS ASSOCIATED WITH PAIN LOSS OFFER NEW TARGETS FOR ANALGESICS. GIVEN THE PROGRESS THAT HAS BEEN MADE, THE COMING YEARS ARE PROMISING BOTH IN TERMS OF TARGETED TREATMENTS FOR PAIN LOSS DISORDERS AND THE DEVELOPMENT OF INNOVATIVE PAIN MEDICINES BASED ON KNOWLEDGE OF THESE GENETIC DISEASES. 2022 7 4758 34 NOVEL TREATMENT STRATEGIES TARGETING MYELIN AND OLIGODENDROCYTE DYSFUNCTION IN SCHIZOPHRENIA. OLIGODENDROCYTES ARE THE GLIAL CELLS RESPONSIBLE FOR THE FORMATION OF THE MYELIN SHEATH AROUND AXONS. DURING NEURODEVELOPMENT, OLIGODENDROCYTES UNDERGO MATURATION AND DIFFERENTIATION, AND LATER REMYELINATION IN ADULTHOOD. ABNORMALITIES IN THESE PROCESSES HAVE BEEN ASSOCIATED WITH BEHAVIORAL AND COGNITIVE DYSFUNCTIONS AND THE DEVELOPMENT OF VARIOUS MENTAL ILLNESSES LIKE SCHIZOPHRENIA. SEVERAL STUDIES HAVE IMPLICATED OLIGODENDROCYTE DYSFUNCTION AND MYELIN ABNORMALITIES IN THE DISORDER, TOGETHER WITH ALTERED EXPRESSION OF MYELIN-RELATED GENES SUCH AS OLIG2, CNP, AND NRG1. HOWEVER, THE MOLECULAR MECHANISMS SUBJACENT OF THESE ALTERATIONS REMAIN ELUSIVE. SCHIZOPHRENIA IS A SEVERE, CHRONIC PSYCHIATRIC DISORDER AFFECTING MORE THAN 23 MILLION INDIVIDUALS WORLDWIDE AND ITS SYMPTOMS USUALLY APPEAR AT THE BEGINNING OF ADULTHOOD. CURRENTLY, THE MAJOR THERAPEUTIC STRATEGY FOR SCHIZOPHRENIA RELIES ON THE USE OF ANTIPSYCHOTICS. DESPITE THEIR WIDESPREAD USE, THE EFFECTS OF ANTIPSYCHOTICS ON GLIAL CELLS, ESPECIALLY OLIGODENDROCYTES, REMAIN UNCLEAR. THUS, IN THIS REVIEW WE HIGHLIGHT THE CURRENT KNOWLEDGE REGARDING OLIGODENDROCYTE DYSFUNCTION IN SCHIZOPHRENIA, COMPILING DATA FROM (EPI)GENETIC STUDIES AND UP-TO-DATE MODELS TO INVESTIGATE THE ROLE OF OLIGODENDROCYTES IN THE DISORDER. IN ADDITION, WE EXAMINED POTENTIAL TARGETS CURRENTLY INVESTIGATED FOR THE IMPROVEMENT OF SCHIZOPHRENIA SYMPTOMS. RESEARCH IN THIS AREA HAS BEEN INVESTIGATING POTENTIAL BENEFICIAL COMPOUNDS, INCLUDING THE D-AMINO ACIDS D-ASPARTATE AND D-SERINE, THAT ACT AS NMDA RECEPTOR AGONISTS, MODULATING THE GLUTAMATERGIC SIGNALING; THE ANTIOXIDANT N-ACETYLCYSTEINE, A PRECURSOR IN THE SYNTHESIS OF GLUTATHIONE, PROTECTING AGAINST THE REDOX IMBALANCE; AS WELL AS LITHIUM, AN INHIBITOR OF GLYCOGEN SYNTHASE KINASE 3BETA (GSK3BETA) SIGNALING, CONTRIBUTING TO OLIGODENDROCYTE SURVIVAL AND FUNCTIONING. IN CONCLUSION, THERE IS STRONG EVIDENCE LINKING OLIGODENDROCYTE DYSFUNCTION TO THE DEVELOPMENT OF SCHIZOPHRENIA. HENCE, A BETTER UNDERSTANDING OF OLIGODENDROCYTE DIFFERENTIATION, AS WELL AS THE EFFECTS OF ANTIPSYCHOTIC MEDICATION IN THESE CELLS, COULD HAVE POTENTIAL IMPLICATIONS FOR UNDERSTANDING THE DEVELOPMENT OF SCHIZOPHRENIA AND FINDING NEW TARGETS FOR DRUG DEVELOPMENT. 2020 8 1495 23 DNA HYPERMETHYLATION OF CELL CYCLE (P15 AND P16) AND APOPTOTIC (P14, P53, DAPK AND TMS1) GENES IN PERIPHERAL BLOOD OF LEUKEMIA PATIENTS. ABERRANT DNA METHYLATION OF TUMOR SUPPRESSOR GENES HAS BEEN REPORTED IN ALL MAJOR TYPES OF LEUKEMIA WITH POTENTIAL INVOLVEMENT IN THE INACTIVATION OF REGULATORY CELL CYCLE AND APOPTOSIS GENES. HOWEVER, MOST OF THE PREVIOUS REPORTS DID NOT SHOW THE EXTENT OF CONCURRENT METHYLATION OF MULTIPLE GENES IN THE FOUR LEUKEMIA TYPES. HERE, WE ANALYZED SIX KEY GENES (P14, P15, P16, P53, DAPK AND TMS1) FOR DNA METHYLATION USING METHYLATION SPECIFIC PCR TO ANALYZE PERIPHERAL BLOOD OF 78 LEUKEMIA PATIENTS (24 CML, 25 CLL, 12 AML, AND 17 ALL) AND 24 HEALTHY VOLUNTEERS. IN CML, METHYLATION WAS DETECTED FOR P15 (11%), P16 (9%), P53 (23%) AND DAPK (23%), IN CLL, P14 (25%), P15 (19%), P16 (12%), P53 (17%) AND DAPK (36%), IN AML, P14 (8%), P15 (45%), P53 (9%) AND DAPK (17%) AND IN ALL, P15 (14%), P16 (8%), AND P53 (8%). THIS STUDY HIGHLIGHTED AN ESSENTIAL ROLE OF DAPK METHYLATION IN CHRONIC LEUKEMIA IN CONTRAST TO P15 METHYLATION IN THE ACUTE CASES, WHEREAS TMS1 HYPERMETHYLATION WAS ABSENT IN ALL CASES. FURTHERMORE, HYPERMETHYLATION OF MULTIPLE GENES PER PATIENT WAS OBSERVED, WITH OBVIOUS SELECTIVENESS IN THE 9P21 CHROMOSOMAL REGION GENES (P14, P15 AND P16). INTERESTINGLY, METHYLATION OF P15 INCREASED THE RISK OF METHYLATION IN P53, AND VICE VERSA, BY FIVE FOLDS (P=0.03) INDICATING POSSIBLE SYNERGISTIC EPIGENETIC DISRUPTION OF DIFFERENT PHASES OF THE CELL CYCLE OR BETWEEN THE CELL CYCLE AND APOPTOSIS. THE INVESTIGATION OF MULTIPLE RELATIONSHIPS BETWEEN METHYLATED GENES MIGHT SHED LIGHT ON TUMOR SPECIFIC INACTIVATION OF THE CELL CYCLE AND APOPTOTIC PATHWAYS. 2014 9 6415 18 THE STUDY OF P16 AND P15 GENE METHYLATION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA AND THEIR QUANTITATIVE EVALUATION IN PLASMA BY REAL-TIME PCR. EPIGENETIC SILENCING OF THE P16 AND P15 GENES BY PROMOTER METHYLATION ARE COMMONLY OBSERVED IN HUMAN EPITHELIAL MALIGNANCIES, INCLUDING HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCC). IN THIS STUDY, A METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP) WAS USED TO EVALUATE THE METHYLATION STATUS OF THE P16 AND P15 GENES IN 73 HNSCC SURGICAL SPECIMENS. P16 AND P15 GENE METHYLATION WAS ALSO EXAMINED IN 29 PAIRED METASTATIC LYMPH NODES AND 29 PAIRED HISTOLOGICALLY, NORMAL RESECTION MARGIN MUCOSAE. THE QUANTITY OF CELL-FREE METHYLATED P16 AND P15 DNA IN THE PLASMA SAMPLES OF 20 HNSCC PATIENTS AND 24 HEALTHY CONTROLS WAS ALSO EXAMINED USING A FLUORESCENCE-BASED REAL-TIME PCR ASSAY. THE FREQUENCIES OF P16 AND P15 METHYLATION IN THE PRIMARY TUMOUR WERE 49% AND 60%, RESPECTIVELY. CONCORDANT METHYLATION OF P16 AND P15 IN TUMOUR SAMPLES AND METASTATIC LYMPH NODES WAS FOUND IN 59 AND 38% OF CASES, RESPECTIVELY. A SIGNIFICANTLY HIGHER PREVALENCE OF P15 METHYLATION WAS FOUND IN HISTOLOGICALLY-NORMAL SURGICAL MARGIN EPITHELIA OF HNSCC PATIENTS WITH CHRONIC SMOKING AND DRINKING HABITS COMPARED WITH NON-SMOKERS AND NON-DRINKERS. IN ADDITION, METHYLATED P16 AND P15 DNA LEVELS WERE SIGNIFICANTLY HIGHER IN THE PLASMA OF HNSCC PATIENTS (MEAN 56 COPIES/ML PLASMA AND 65 COPIES/ML PLASMA, RESPECTIVELY) COMPARED WITH NORMAL CONTROLS (MEAN 6 COPIES/ML PLASMA AND 16 COPIES/ML PLASMA, RESPECTIVELY). IN CONCLUSION, PROMOTER METHYLATION OF THE P16 AND P15 GENES IS INVOLVED IN THE PATHOGENESIS OF HNSCC AND MAY BE RELATED TO CHRONIC SMOKING AND DRINKING. THE DIFFERENTIAL LEVELS OF METHYLATED P16 AND P15 DNA IN PLASMA MIGHT BE POTENTIAL USEFUL MARKERS IN SCREENING HIGH-RISK POPULATIONS FOR EARLY HNSCC AND MONITORING THEIR TREATMENT RESPONSE. 2003 10 6660 28 UPREGULATION OF CXCR4 THROUGH PROMOTER DEMETHYLATION CONTRIBUTES TO INFLAMMATORY HYPERALGESIA IN RATS. AIM AND METHODS: CHRONIC PAIN ASSOCIATED WITH INFLAMMATION IS A COMMON CLINICAL PROBLEM, AND THE UNDERLYING MECHANISMS YET ARE INCOMPLETELY DEFINED. DNA METHYLATION HAS BEEN IMPLICATED IN THE PATHOGENESIS OF CHRONIC PAIN. HOWEVER, THE SPECIFIC GENES REGULATED BY DNA METHYLATION UNDER INFLAMMATORY PAIN CONDITION REMAIN LARGELY UNKNOWN. HERE, WE INVESTIGATED HOW CHEMOKINE RECEPTOR CXCR4 EXPRESSION IS REGULATED BY DNA METHYLATION AND HOW IT CONTRIBUTES TO INFLAMMATORY PAIN INDUCED BY COMPLETE FREUND'S ADJUVANT (CFA) IN RATS. RESULTS: INTRAPLANTAR INJECTION OF CFA COULD NOT ONLY INDUCE SIGNIFICANT HYPERALGESIA IN RATS, BUT ALSO SIGNIFICANTLY INCREASE THE EXPRESSION OF CXCR4 MRNA AND PROTEIN IN THE DORSAL ROOT GANGLION (DRG). INTRATHECAL INJECTION OF CXCR4 ANTAGONIST AMD3100 SIGNIFICANTLY RELIEVED HYPERALGESIA IN INFLAMMATORY RATS IN A TIME- AND DOSE-DEPENDENT MANNER. BISULFITE SEQUENCING AND METHYLATION-SPECIFIC PCR DEMONSTRATE THAT CFA INJECTION LED TO A SIGNIFICANT DEMETHYLATION OF CPG ISLAND AT CXCR4 GENE PROMOTER. CONSISTENTLY, THE EXPRESSION OF DNMT3B WAS SIGNIFICANTLY DOWNREGULATED AFTER CFA INJECTION. ONLINE SOFTWARE PREDICTION REVEALS THREE BINDING SITES OF P65 IN THE CPG ISLAND OF CXCR4 GENE PROMOTER, WHICH HAS CONFIRMED BY THE CHROMATIN IMMUNOPRECIPITATION ASSAY, CFA TREATMENT SIGNIFICANTLY INCREASES THE RECRUITMENT OF P65 TO CXCR4 GENE PROMOTER. INHIBITION OF NF-KB SIGNALING USING P65 INHIBITOR PYRROLIDINE DITHIOCARBAMATE SIGNIFICANTLY PREVENTED THE INCREASES OF THE CXCR4 EXPRESSION. CONCLUSION: UPREGULATION OF CXCR4 EXPRESSION DUE TO PROMOTER DEMETHYLATION FOLLOWED BY INCREASED RECRUITMENT OF P65 TO PROMOTER OF CXCR4 GENE CONTRIBUTES TO INFLAMMATORY HYPERALGESIA. THESE FINDINGS PROVIDE A THEORETICAL BASIS FOR THE TREATMENT OF CHRONIC PAIN FROM AN EPIGENETIC PERSPECTIVE. 2018 11 500 18 ASSOCIATION BETWEEN NEUROPATHIC PAIN CHARACTERISTICS AND DNA METHYLATION OF TRANSIENT RECEPTOR POTENTIAL ANKYRIN 1 IN HUMAN PERIPHERAL BLOOD. ELUCIDATION OF EPIGENETIC MECHANISMS CORRELATING WITH NEUROPATHIC PAIN IN HUMANS IS CRUCIAL FOR THE PREVENTION AND TREATMENT OF THIS TREATMENT-RESISTANT PAIN STATE. IN THE PRESENT STUDY, ASSOCIATIONS BETWEEN NEUROPATHIC PAIN CHARACTERISTICS AND DNA METHYLATION OF THE TRANSIENT RECEPTOR POTENTIAL ANKYRIN 1 (TRPA1) GENE WERE EVALUATED IN CHRONIC PAIN PATIENTS AND PREOPERATIVE PATIENTS. PAIN AND PSYCHOLOGICAL STATES WERE PROSPECTIVELY ASSESSED IN PATIENTS WHO SUFFERED CHRONIC PAIN OR WERE SCHEDULED FOR THORACIC SURGERY. NEUROPATHIC CHARACTERISTICS WERE ASSESSED USING THE DOULEUR NEUROPATHIQUE 4 (DN4) QUESTIONNAIRE. DNA METHYLATION LEVELS OF THE CPG ISLANDS IN THE TRPA1 GENE WERE EXAMINED USING WHOLE BLOOD. FORTY-EIGHT ADULT PATIENTS WERE ENROLLED IN THIS STUDY. INCREASES IN DNA METHYLATION RATES AT CPG -51 SHOWED POSITIVE CORRELATIONS WITH INCREASES IN THE DN4 SCORE BOTH IN PREOPERATIVE AND CHRONIC PAIN PATIENTS. COMBINED METHYLATION RATES AT CPG -51 IN THESE PATIENTS ALSO SIGNIFICANTLY INCREASED TOGETHER WITH INCREASE IN DN4 SCORES. NEUROPATHIC PAIN CHARACTERISTICS ARE LIKELY ASSOCIATED WITH METHYLATION RATES AT THE PROMOTER REGION OF THE TRPA1 GENE IN HUMAN PERIPHERAL BLOOD. 2020 12 5459 21 RESEARCH ON THE EPIGENETIC REGULATION MECHANISM OF THE PTPN6 GENE IN ADVANCED CHRONIC MYELOID LEUKAEMIA. PTPN6, A TYROSINE PHOSPHATASE PROTEIN, PLAYS A NEGATIVE ROLE IN CELL SIGNAL TRANSDUCTION AND IS NEGATIVELY CORRELATED WITH TUMOUR FORMATION AND GROWTH. HOWEVER, EPIGENETIC REGULATION MECHANISM OF THE PTPN6 GENE IN ADVANCED CHRONIC MYELOID LEUKAEMIA (CML) REMAINS UNCLEAR. THIS STUDY INVESTIGATED BONE MARROW OR BLOOD SAMPLES FROM 44 CML PATIENTS AND 10 HEALTHY VOLUNTEERS. KCL22 AND K562 CELLS WERE CULTURED AND TREATED WITH DEMETHYLATION DRUGS AND HISTONE DEACETYLASE INHIBITORS. REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR), METHYLATION-SPECIFIC PCR, BISULFITE SEQUENCING PCR, WESTERN BLOTTING, CO-IMMUNOPRECIPITATION AND CHROMATIN IMMUNOPRECIPITATION (CHIP) WAS PERFORMED. PTPN6 WAS DOWN-REGULATED IN CELL LINES AND PATIENTS WITH ADVANCED PHASE CML, WHEREAS DNMT1, DNMT3A, MECP2, MBD2 AND HDAC1 WERE UP-REGULATED. TREATMENT WITH 5-AZACYTIDINE, DECITABINE, SODIUM VALPROATE AND LBH589 INCREASED PTPN6 EXPRESSION, BUT DECREASED THAT OF DNMT1, DNMT3A, MECP2, MBD2 AND HDAC1. IMMUNOPRECIPITATION AND MASS SPECTROMETRY SHOWED THAT HDAC1 COMBINED DIRECTLY WITH PTPN6. CHIP-SEQ SHOWED THAT HDAC1 DID NOT COMBINE WITH THE PROMOTER REGION OF PTPN6, WHILE MAPK, AKT, STAT5, JAK2 AND MYC PROMOTER REGIONS ALL COMBINED WITH HDAC1. PTPN6 IS ASSOCIATED WITH PROGRESSION OF CML. LOW EXPRESSION LEVEL OF PTPN6 WAS ASSOCIATED WITH DNA METHYLATION AND REGULATED BY HISTONE ACETYLATION. HDAC1 PARTICIPATES IN THE REGULATION OF PTPN6. 2017 13 2326 25 EPIGENETIC REGULATION OF HOTAIR IN ADVANCED CHRONIC MYELOID LEUKEMIA. PURPOSE: CHRONIC MYELOID LEUKEMIA (CML) ACCOUNTS FOR ~10% OF LEUKEMIA CASES, AND ITS PROGRESSION INVOLVES EPIGENETIC GENE REGULATION. THIS STUDY INVESTIGATED EPIGENETIC REGULATION OF HOTAIR AND ITS TARGET MICRORNA, MIR-143, IN ADVANCED CML. PATIENTS AND METHODS: WE FIRST ISOLATED BONE MARROW MONONUCLEAR CELLS FROM 70 PATIENTS WITH DIFFERENT PHASES OF CML AND FROM HEALTHY DONORS AS NORMAL CONTROL; WE ALSO CULTURED K562 AND KCL22 CELLS, TREATED WITH DEMETHYLATION DRUG; MTT ASSAY, FLOW CYTOMETRY, QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QPCR), METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP), WESTERN BLOT, LUCIFERASE ASSAY, RNA PULL-DOWN ASSAY AND RNA-BINDING PROTEIN IMMUNOPRECIPITATION (RIP) ASSAY WERE PERFORMED. RESULT: AS MEASURED BY QPCR, HOTAIR EXPRESSION IN K562 CELLS, KCL22 CELLS, AND SAMPLES FROM CASES OF ADVANCED-STAGE CML INCREASED WITH LEVELS OF SEVERAL DNA METHYLTRANSFERASES AND HISTONE DEACETYLATES, INCLUDING DNMT1, DNMT3A, HDAC1, EZH2, AND LSD1, AND MIR-143 LEVELS WERE DECREASED AND HOTAIR LEVELS WERE INCREASED. TREATMENT WITH 5-AZACYTIDINE, A DNA METHYLATION INHIBITOR, DECREASED DNMT1, DNMT3A, HDAC1, EZH2, LSD1 MRNA, PROTEIN LEVELS, AND HOTAIR MRNA LEVELS BUT INCREASED MIR-143 LEVELS. HOTAIR KNOCKDOWN AND MIR-143 OVEREXPRESSION BOTH INHIBITED PROLIFERATION AND PROMOTED APOPTOSIS IN KCL22 AND K562 CELLS THROUGH THE PI3K/AKT PATHWAY. RNA PULL-DOWN, MASS SPECTROMETRY, AND RIP ASSAYS SHOWED THAT HOTAIR INTERACTED WITH EZH2 AND LSD1. A DUAL-LUCIFERASE ASSAY DEMONSTRATED THAT HOTAIR INTERACTED WITH MIR-143. CONCLUSION: OUR FINDINGS DEMONSTRATE THE KEY EPIGENETIC INTERACTIONS OF HOTAIR RELATED TO CML PROGRESSION AND SUGGEST HOTAIR AS A POTENTIAL THERAPEUTIC TARGET FOR ADVANCED CML. FURTHERMORE, OUR RESULTS SUPPORT THE USE OF DEMETHYLATION DRUGS AS A CML TREATMENT STRATEGY. 2018 14 6585 26 TRPV4-MEDIATED ANTI-NOCICEPTIVE EFFECT OF SUBERANILOHYDROXAMIC ACID ON MECHANICAL PAIN. BIOLOGICAL EFFECTS OF SUBERANILOHYDROXAMIC ACID (SAHA) HAVE MAINLY BEEN OBSERVED IN THE CONTEXT OF TUMOR SUPPRESSION VIA EPIGENETIC MECHANISMS, BUT OTHER POTENTIAL OUTCOMES FROM ITS USE HAVE ALSO BEEN PROPOSED IN DIFFERENT FIELDS SUCH AS PAIN MODULATION. HERE, WE TRIED TO UNDERSTAND WHETHER SAHA MODULATES SPECIFIC PAIN MODALITIES BY A NON-EPIGENETIC UNKNOWN MECHANISM. FROM 24 H COMPLETE FREUND'S ADJUVANT (CFA)-INFLAMED HIND PAWS OF MICE, MECHANICAL AND THERMAL INFLAMMATORY PAIN INDICES WERE COLLECTED WITH OR WITHOUT IMMEDIATE INTRAPLANTAR INJECTION OF SAHA. TO EXAMINE THE ACTION OF SAHA ON SENSORY RECEPTOR-SPECIFIC PAIN, TRANSIENT RECEPTOR POTENTIAL (TRP) ION CHANNEL-MEDIATED PAIN INDICES WERE COLLECTED IN THE SAME MANNER OF INTRAPLANTAR TREATMENT. ACTIVITIES OF PRIMARILY CULTURED SENSORY NEURONS AND HETEROLOGOUS CELLS TRANSFECTED WITH TRP CHANNELS WERE MONITORED TO DETERMINE THE MOLECULAR MECHANISM UNDERLYING THE PAIN-MODULATING EFFECT OF SAHA. AS A RESULT, IMMEDIATE AND LOCALIZED PRETREATMENT WITH SAHA, AVOIDING AN EPIGENETIC INTERVENTION, ACUTELY ATTENUATED MECHANICAL INFLAMMATORY PAIN AND RECEPTOR-SPECIFIC PAIN EVOKED BY INJECTION OF A TRP CHANNEL AGONIST IN ANIMAL MODELS. WE SHOW THAT A COMPONENT OF THE MECHANISMS INVOLVES TRPV4 INHIBITION BASED ON IN VITRO INTRACELLULAR CA(2+) IMAGING AND ELECTROPHYSIOLOGICAL ASSESSMENTS WITH HETEROLOGOUS EXPRESSION SYSTEMS AND CULTURED SENSORY NEURONS. TAKEN TOGETHER, THE PRESENT STUDY PROVIDES EVIDENCE OF A NOVEL OFF-TARGET ACTION AND ITS MECHANISM OF SAHA IN ITS MODALITY-SPECIFIC ANTI-NOCICEPTIVE EFFECT AND SUGGESTS THE UTILITY OF THIS COMPOUND FOR PHARMACOLOGICAL MODULATION OF PAIN. 2019 15 1631 27 DNMT3A METHYLATION IN NEUROPATHIC PAIN. BACKGROUND: MU OPIOID RECEPTOR (MOR) PLAYS A CRUCIAL ROLE IN MEDIATING ANALGESIC EFFECTS OF OPIOIDS AND IS CLOSELY ASSOCIATED WITH THE PATHOLOGIES OF NEUROPATHIC PAIN. PREVIOUS STUDIES HAVE REPORTED THAT PERIPHERAL NERVE INJURY DOWNREGULATES MOR EXPRESSION, BUT THE EPIGENETIC MECHANISMS REMAIN UNKNOWN. OBJECTIVE: THEREFORE, WE INVESTIGATED DNA METHYLTRANSFERASE3A (DNMT3A) EXPRESSION OR METHYLATION CHANGES WITHIN MOR PROMOTER IN THE SPINAL CORD IN A NEUROPATHIC PAIN INDUCED BY A CHRONIC CONSTRICTION INJURY (CCI) MOUSE MODEL AND FURTHER DETERMINED WHETHER THESE INJURY-ASSOCIATED CHANGES ARE REVERSIBLE BY PHARMACOLOGICAL INTERVENTIONS. METHODS: A CCI MOUSE MODEL WAS ESTABLISHED AND TISSUE SPECIMENS OF LUMBAR SPINAL CORDS WERE COLLECTED. THE NOCICEPTION THRESHOLD WAS EVALUATED BY A MODEL HEATED 400 BASE. DNMT3A AND MOR MRNA AND PROTEIN LEVEL WERE DETECTED BY REAL-TIME-POLYMERASE CHAIN REACTION AND WESTERN BLOT, RESPECTIVELY. METHYLATION OF DNMT3A GENE WAS MEASURED BY METHYLATION-SPECIFIC PCR. RESULTS: OUR DATA SHOWED THAT CHRONIC NERVE INJURY LED TO A SIGNIFICANT UPREGULATION OF DNMT3A EXPRESSION THAT WAS ASSOCIATED WITH INCREASED METHYLATION OF MOR GENE PROMOTER AND DECREASED MOR PROTEIN EXPRESSION IN THE SPINAL CORD. INHIBITION OF DNMT3A CATALYTIC ACTIVITY WITH DNMT INHIBITOR RG108 SIGNIFICANTLY BLOCKED THE INCREASE IN METHYLATION OF THE MOR PROMOTER, AND THEN UPREGULATED MOR EXPRESSION AND ATTENUATED THERMAL HYPERALGESIA IN NEUROPATHIC PAIN MICE. CONCLUSION: THIS STUDY DEMONSTRATES THAT AN INCREASE OF DNMT3A EXPRESSION AND MOR METHYLATION EPIGENETICALLY PLAY AN IMPORTANT ROLE IN NEUROPATHIC PAIN. TARGETING DNMT3A TO THE PROMOTER OF MOR GENE BY DNMT INHIBITOR MAY BE A PROMISING APPROACH TO THE DEVELOPMENT OF NEW NEUROPATHIC PAIN THERAPY. 2017 16 2847 16 FREQUENT P15 PROMOTER METHYLATION IN TUMOR AND PERIPHERAL BLOOD FROM HEPATOCELLULAR CARCINOMA PATIENTS. WE PROSPECTIVELY ANALYZED P15 METHYLATION PATTERNS IN 25 SURGICALLY RESECTED TUMORS AND 130 PLASMA, SERUM, AND BUFFY COAT SAMPLES FROM HEPATOCELLULAR CARCINOMA (HCC) PATIENTS, CONTROLS WITH CHRONIC HEPATITIS/CIRRHOSIS, AND HEALTHY SUBJECTS. USING METHYLATION-SPECIFIC PCR, WE DEMONSTRATED FOR THE FIRST TIME P15 PROMOTER METHYLATION IN 64% OF TUMORS AND 25% (4 OF 16) OF PATIENTS' PLASMA AND SERUM SAMPLES. CONCURRENT P15 AND P16 METHYLATION WAS SHOWN IN 48% OF TUMORS, AND P15/P16 METHYLATION WAS DETECTED IN THE PLASMA/SERUM OF 92% (11 OF 12) OF PATIENTS. OF NOTE, 75% OF 12 PATIENTS WITH CONCURRENT TUMOR METHYLATION DEVELOPED CLINICAL METASTASIS/RECURRENCE (P = 0.027). IN BUFFY COAT SAMPLES, P15 METHYLATION WAS DETECTED IN ALL EIGHT PATIENTS WITH TUMOR P15 METHYLATION, SUGGESTING THE PRESENCE OF CIRCULATING TUMOR CELLS. NONE OF THE CONTROL SAMPLES WERE METHYLATION POSITIVE. OUR DATA UNDERSCORE THE IMPORTANT ROLE(S) OF P15 AND P16 METHYLATION IN HEPATOCARCINOGENESIS AND TUMOR PROGRESSION. AMONG 92% (23 OF 25) OF PATIENTS WITH TUMOR P15/P16 METHYLATION, CIRCULATING TUMOR DNA AND HCC CELLS WERE DETECTED IN THE PERIPHERAL BLOOD OF 87% (20 OF 23) OF PATIENTS. THE COMBINATION OF THESE EPIGENETIC MARKERS MAY PROVE VALUABLE FOR NONINVASIVE HCC DIAGNOSIS AND DISEASE MONITORING. 2000 17 3154 29 GLUN2B/CAMKII MEDIATES CFA-INDUCED HYPERALGESIA VIA HDAC4-MODIFIED SPINAL COX2 TRANSCRIPTION. HISTONE DEACETYLASE 4 (HDAC4), WHICH ACTIVELY SHUTTLES BETWEEN THE NUCLEUS AND CYTOPLASM, IS AN ATTRACTIVE CANDIDATE FOR A REPRESSOR MECHANISM IN EPIGENETIC MODIFICATION. HOWEVER, THE POTENTIAL ROLE OF HDAC4-DEPENDENT EPIGENETICS IN THE NEURAL PLASTICITY UNDERLYING THE DEVELOPMENT OF INFLAMMATORY PAIN HAS NOT BEEN WELL ESTABLISHED. BY INJECTING COMPLETE FREUND'S ADJUVANT (CFA) INTO THE HIND-PAW OF SPRAGUE-DAWLEY RATS (200-250 G), WE FOUND ANIMALS DISPLAYED BEHAVIORAL HYPERALGESIA WAS ACCOMPANIED WITH HDAC4 PHOSPHORYLATION AND CYTOPLASMIC REDISTRIBUTION IN THE DORSAL HORN NEURONS. CYTOPLASMIC HDAC4 RETENTION LED TO ITS UNCOUPLING WITH THE COX2 PROMOTER, HENCE PROMPTING SPINAL COX2 TRANSCRIPTION AND EXPRESSION IN THE DORSAL HORN. MOREOVER, THE GLUN2B-BEARING N-METHYL-D-ASPARTATE RECEPTOR (GLUN2B-NMDAR)/CALMODULIN-DEPENDENT PROTEIN KINASE II (CAMKII) ACTED AS AN UPSTREAM CASCADE TO FACILITATE HDAC4 PHOSPHORYLATION/REDISTRIBUTION-ASSOCIATED SPINAL COX2 EXPRESSION AFTER INFLAMMATORY INSULTS. THE RESULTS OF THIS PILOT STUDY DEMONSTRATED THAT THE DEVELOPMENT AND/OR MAINTENANCE OF INFLAMMATORY PAIN INVOLVED THE SPINAL HDAC4-DEPENDENT EPIGENETIC MECHANISMS. OUR FINDINGS OPEN UP A NEW AVENUE FOR THE DEVELOPMENT OF A NOVEL MEDICAL STRATEGY FOR THE RELIEF OF INFLAMMATORY PAIN. 2018 18 1120 22 COMPARISON OF DIFFERENT HISTONE DEACETYLASE INHIBITORS IN ATTENUATING INFLAMMATORY PAIN IN RATS. HISTONE DEACETYLASE INHIBITORS (HDACIS), WHICH INTERFERE WITH THE EPIGENETIC PROCESS OF HISTONE ACETYLATION, HAVE SHOWN ANALGESIC EFFECTS IN ANIMAL MODELS OF PERSISTENT PAIN. THE HDAC FAMILY COMPRISES 18 GENES; HOWEVER, THE DIFFERENT EFFECTS OF DISTINCT CLASSES OF HDACIS ON PAIN RELIEF REMAIN UNCLEAR. THE AIM OF THIS STUDY WAS TO DETERMINE THE EFFICACY OF THESE HDACIS ON ATTENUATING THERMAL HYPERALGESIA IN PERSISTENT INFLAMMATORY PAIN. PERSISTENT INFLAMMATORY PAIN WAS INDUCED BY INJECTING COMPLETE FREUND'S ADJUVANT (CFA) INTO THE LEFT HIND PAW OF RATS. THEN, HDACIS TARGETING CLASS I (ENTINOSTAT (MS-275)) AND CLASS IIA (SODIUM BUTYRATE, VALPROIC ACID (VPA), AND 4-PHENYLBUTYRIC ACID (4-PBA)), OR CLASS II (SUBEROYLANILIDE HYDOXAMIC ACID (SAHA), TRICHOSTATIN A (TSA), AND DACINOSTAT (LAQ824)) WERE ADMINISTERED INTRAPERITONEALLY ONCE DAILY FOR 3 OR 4 DAYS. WE FOUND THAT THE INJECTION OF SAHA ONCE A DAY FOR 3 DAYS SIGNIFICANTLY ATTENUATED CFA-INDUCED THERMAL HYPERALGESIA FROM DAY 4 AND LASTED 7 DAYS. IN COMPARISON WITH SAHA, SUPPRESSION OF HYPERALGESIA BY 4-PBA PEAKED ON DAY 2, WHEREAS THAT BY MS-275 OCCURRED ON DAYS 5 AND 6. FATIGUE WAS A SERIOUS SIDE EFFECT SEEN WITH MS-275. THESE FINDINGS WILL BE BENEFICIAL FOR OPTIMIZING THE SELECTION OF SPECIFIC HDACIS IN MEDICAL FIELDS SUCH AS PAIN MEDICINE AND NEUROPSYCHIATRY. 2019 19 2452 22 EPIGENETIC SUPPRESSION OF POTASSIUM-CHLORIDE CO-TRANSPORTER 2 EXPRESSION IN INFLAMMATORY PAIN INDUCED BY COMPLETE FREUND'S ADJUVANT (CFA). BACKGROUND: MULTIPLE MECHANISMS CONTRIBUTE TO THE STIMULUS-EVOKED PAIN HYPERSENSITIVITY THAT MAY BE EXPERIENCED AFTER PERIPHERAL INFLAMMATION. PERSISTENT PATHOLOGICAL STIMULI IN MANY PAIN CONDITIONS AFFECT THE EXPRESSION OF CERTAIN GENES THROUGH EPIGENETIC ALTERNATIONS. THE MAIN PURPOSE OF OUR STUDY WAS TO INVESTIGATE THE ROLE OF EPIGENETIC MODIFICATION ON POTASSIUM-CHLORIDE CO-TRANSPORTER 2 (KCC2) GENE EXPRESSION IN THE PERSISTENCE OF INFLAMMATORY PAIN. METHODS: PERSISTENT INFLAMMATORY PAIN WAS INDUCED THROUGH THE INJECTION OF COMPLETE FREUND'S ADJUVANT (CFA) IN THE LEFT HIND PAW OF RATS. ACETYL-HISTONE H3 AND H4 LEVEL WAS DETERMINED BY CHROMATIN IMMUNOPRECIPITATION IN THE SPINAL DORSAL HORN. PAIN BEHAVIOUR AND INHIBITORY SYNAPTIC FUNCTION OF SPINAL CORD WERE DETERMINED BEFORE AND AFTER CFA INJECTION. KCC2 EXPRESSION WAS DETERMINED BY REAL TIME RT-PCR AND WESTERN BLOT. INTRATHECAL KCC2 SIRNA (2 MUG PER 10 MUL PER RAT) OR HDAC INHIBITOR (10 MUG PER 10 MUL PER RAT) WAS INJECTED ONCE DAILY FOR 3 DAYS BEFORE CFA INJECTION. RESULTS: PERSISTENT INFLAMMATORY PAIN EPIGENETICALLY SUPPRESSED KCC2 EXPRESSION THROUGH HISTONE DEACETYLASE (HDAC)-MEDIATED HISTONE HYPOACETYLATION, RESULTING IN DECREASED INHIBITORY SIGNALLING EFFICACY. KCC2 KNOCK-DOWN CAUSED BY INTRATHECAL ADMINISTRATION OF KCC2 SIRNA IN NAIVE RATS REDUCED KCC2 EXPRESSION IN THE SPINAL CORD, LEADING TO SENSITIZED PAIN BEHAVIOURS AND IMPAIRED INHIBITORY SYNAPTIC TRANSMISSION IN THEIR SPINAL CORDS. MOREOVER, INTRATHECAL HDAC INHIBITOR INJECTION IN CFA RATS INCREASED KCC2 EXPRESSION, PARTIALLY RESTORING THE SPINAL INHIBITORY SYNAPTIC TRANSMISSION AND RELIEVING THE SENSITIZED PAIN BEHAVIOUR. CONCLUSION: THESE FINDINGS SUGGEST THAT THE TRANSCRIPTION OF SPINAL KCC2 IS REGULATED BY HISTONE ACETYLATION EPIGENETICALLY FOLLOWING CFA. SIGNIFICANCE: PERSISTENT PAIN SUPPRESSES KCC2 EXPRESSION THROUGH HDAC-MEDIATED HISTONE HYPOACETYLATION AND CONSEQUENTLY IMPAIRS THE INHIBITORY FUNCTION OF INHIBITORY INTERNEURONS. DRUGS SUCH AS HDAC INHIBITORS THAT SUPPRESS THE INFLUENCES OF PERSISTENT PAIN ON THE EXPRESSION OF KCC2 MAY SERVE AS A NOVEL ANALGESIC. 2017 20 5600 23 ROLES OF VOLTAGE-DEPENDENT SODIUM CHANNELS IN NEURONAL DEVELOPMENT, PAIN, AND NEURODEGENERATION. BESIDES INITIATING AND PROPAGATING ACTION POTENTIALS IN ESTABLISHED NEURONAL CIRCUITS, VOLTAGE-DEPENDENT SODIUM CHANNELS SCULPT AND BOLSTER THE FUNCTIONAL NEURONAL NETWORK FROM EARLY IN EMBRYONIC DEVELOPMENT THROUGH ADULTHOOD (E.G., DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS INTO OLIGODENDROCYTES, MYELINATING AXON; COMPETITION BETWEEN NEIGHBORING EQUIPOTENTIAL NEURITES FOR DEVELOPMENT INTO A SINGLE AXON; ENHANCING AND OPPOSING FUNCTIONAL INTERACTIONS WITH ATTRACTIVE AND REPULSIVE MOLECULES FOR AXON PATHFINDING; EXTENDING AND RETRACTING TERMINAL ARBORIZATION OF AXON FOR CORRECT SYNAPSE FORMATION; EXPERIENCE-DRIVEN COGNITION; NEURONAL SURVIVAL; AND REMYELINATION OF DEMYELINATED AXONS). SURPRISINGLY, DIFFERENT PATTERNS OF ACTION POTENTIALS DIRECT HOMEOSTASIS-BASED EPIGENETIC SELECTION FOR NEUROTRANSMITTER PHENOTYPE, THUS EXCITABILITY BY SODIUM CHANNELS SPECIFYING EXPRESSION OF INHIBITORY NEUROTRANSMITTERS. MECHANISMS FOR THESE PLEIOTROPIC EFFECTS OF SODIUM CHANNELS INCLUDE RECIPROCAL INTERACTIONS BETWEEN NEURONS AND GLIA VIA NEUROTRANSMITTERS, GROWTH FACTORS, AND CYTOKINES AT SYNAPSES AND AXONS. SODIUM CHANNELOPATHIES CAUSING PAIN (E.G., ALLODYNIA) AND NEURODEGENERATION (E.G., MULTIPLE SCLEROSIS) DERIVE FROM 1) ELECTROPHYSIOLOGICAL DISTURBANCES BY INSULTS (E.G., ISCHEMIA/HYPOXIA, TOXINS, AND ANTIBODIES); 2) LOSS-OF-PHYSIOLOGICAL FUNCTION OR GAIN-OF-PATHOLOGICAL FUNCTION OF MUTANT SODIUM CHANNEL PROTEINS; 3) SPATIOTEMPORAL INAPPROPRIATE EXPRESSION OF NORMAL SODIUM CHANNEL PROTEINS; OR 4) DE-REPRESSED EXPRESSION OF OTHERWISE SILENT SODIUM CHANNEL GENES. NA(V)1.7 PROVED TO ACCOUNT FOR PAIN IN HUMAN ERYTHERMALGIA AND INFLAMMATION, BEING THE CONVINCING MOLECULAR TARGET OF PAIN TREATMENT. 2006